Vandortuzumab, a novel immunoglobulin, is an intriguing therapeutic compound targeting CD40, a key molecule involved in immune reaction. This mechanism of action entails inhibiting CD40 signaling, seemingly leading to https://www.targetmol.com/compound/vandortuzumab